Activating Transcription Factor 6 (CT) Blocking Peptide
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Product Concentration 0.2 mg/ml Amino Acid Location 16 amino acids near the carboxy terminus of human ATF6. Formulation This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Storage and Handling Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient Amino Acid Sequence 16 amino acids near the carboxy terminus of human ATF6. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionBackground Activating Transcription Factor 6 peptide is applicable as a control peptide for blocking antibody binding in Western blotting. References & Citations1. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004; 5:752-60.
2. Dreuw A, Radtke S, Pflanz S, et al. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J. Biol. Chem. 2004; 279:36112-20.
3. Diveu C, Lak-Hal AH, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur. Cytokine Netw. 2004; 15:291-302.
4. Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2006; 117:418-25. |
Related Products
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
